---
title: "Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295233040.md"
description: "Princeton, New Jersey on August 7, 2026 - Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical firm specializing in developing and marketing treatments for rare diseases with unmet medical requirements, shared its latest developments."
datetime: "2026-08-07T11:56:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295233040.md)
  - [en](https://longbridge.com/en/news/295233040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295233040.md)
generator: "portal-rs"
---

# Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Princeton, New Jersey on August 7, 2026 - Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical firm specializing in developing and marketing treatments for rare diseases with unmet medical requirements, shared its latest developments.

### Related Stocks

- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)

## Related News & Research

- [Soligenix Q2 net loss narrows as R&D expenses fall](https://longbridge.com/en/news/295228776.md)
- [SOLIGENIX, INC. 3Q 2026: Revenue $0 EPS $(0.12) — 10-Q Summary](https://longbridge.com/en/news/295273764.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [11:25 ETILD Day 2026 Spotlights Precision Medicine's Potential to Transform Patient Care](https://longbridge.com/en/news/296512797.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**